Frazier Life Sciences XI, L.P. purchased $10.0M of ATTO

Frazier Life Sciences XI, L.P. purchased 588,235 shares of Attovia Therapeutics, Inc. (ATTO) at $17.00 ($10.00M total) on 2026-08-06.

Original reporting
SEC EDGAR · Frazier Life Sciences XI, L.P.
Published Aug 6, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATTO
Neutral
medium confidence
Mentioned
$ATTO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATTONeutralLow
01

Why it matters

The newest fact is the dated open-market purchase by a 10% owner at a specified price and share count; it can slightly influence sentiment but lacks fundamental new information.

02

Market read

Traders may note accumulation by a significant holder, but there is no accompanying operational or financial catalyst in the text.

03

What to watch

The article does not state motivations, lockups, or whether the buyer’s broader position is changing materially beyond the post-transaction share count.

Relevance 7/10Novelty 5/10Timing: filed 2026-08-06, transaction dated 2026-08-06

Background

This is an SEC Form 4 insider transaction disclosure for Attovia Therapeutics, Inc. (ATTO).

Company-level read

Ticker impact

$ATTONeutralMedium confidence
Context

Frazier Life Sciences XI, a 10% owner, bought 588,235 ATTO shares on 2026-08-06 at $17.00/share via an open-market purchase.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and modest.

Evidence & confidence

Form 4 open-market purchases can reflect conviction, but without accompanying company-specific news (trial, contract, guidance) the incremental trading signal is usually small.

Market effects

No sector read-through is provided beyond a single biotech/therapeutics issuer’s large-holder activity.

None indicated.

None indicated.

Counterpoint

A large-holder open-market purchase may be routine portfolio rebalancing rather than a forward-looking signal.

Key entities

  • Attovia Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Frazier Life Sciences XI, L.P.

    Reported open-market purchase of ATTO shares on 2026-08-06.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ATTOMed

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase

$ATTOMedAI 8/10

Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials

Attovia Therapeutics (ATTO) reported sustained itch relief in a small study for its drug ATTO-1310, with no serious adverse events related to the treatment. The company plans phase 2 trials with 300 patients in one study and 255 in another, aiming for quarterly maintenance dosing. Attovia expects data from a phase 1b study in 2027 and has a cash runway into 2030. The company is developing antibody-based treatments for immune-mediated and inflammatory diseases.

$ATTOHighAI 9/10

Attovia reports 12-week data from ATTO-1310 itch therapy trial

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week Phase 1b trial results for ATTO-1310, an anti-IL-31 therapy. In chronic pruritus patients, 82% of treated patients saw a 4-point reduction in itch versus 22% with placebo. In high-itch atopic dermatitis patients, 44% of treated patients achieved a 4-point reduction versus 75% with placebo. The drug was generally well-tolerated, with plans for Phase 2 trials in 2027.

$ATTOMedAI 8/10

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of

$ATTOMedAI 8/10

Wall Street analysts bullish on Attovia as itch drug data fuel biotech optimism

Attovia Therapeutics received bullish ratings from Citi, Morgan Stanley, and RBC, with price targets ranging from $30 to $45, citing promising early data for its chronic-itch drug ATTO-1310 and its antibody platform. The stock, trading around $21, has significant upside potential according to analysts. The company has $420M in cash post-IPO, reducing near-term financing concerns. Analysts caution about clinical-stage risks, including trial outcomes and competition.